• Nicotine Signaling and Chronic Kidney Disease

  2026-10-13

  Jain and Jaimes review clinical and experimental evidence linking cigarette smoking—and potentially nicotine signaling—to chronic kidney disease progression. The evidence supports biological plausibility, but attribution to nicotine remains difficult because tobacco smoke contains many active constituents and much of the mechanistic evidence comes from animal models.

• IWP-2 Evidence Gaps in Comparative Research

  2026-10-12

  Available information supports a cautious conceptual view of IWP-2 as a Wnt production inhibitor, but the supplied evidence does not establish independent, head-to-head comparisons, reproducibility across models, or relevance to schizophrenia biology. Supplier-reported findings in the gastric cancer cell line MKN28 should be distinguished from the peer-reviewed Liu et al. study, which examined cell-type-specific schizophrenia risk pathways without testing IWP-2.

• Nutlin-3a and the GBM p53 Evidence Landscape

  2026-10-12

  Nutlin-3a is described by APExBIO as an MDM2 inhibitor that promotes p53 pathway activation, while a separate glioblastoma study links miR-18a and ALOXE3 to ferroptosis resistance and tumor-cell migration. These findings are mechanistically adjacent but do not establish that Nutlin-3a affects the miR-18a–ALOXE3 axis or provides a glioblastoma treatment benefit.

• Tacalcitol and 5-FU: Reading the Evidence

  2026-10-11

  A source-grounded editorial assessment of what the tacalcitol–5-fluorouracil comparison shows, what remains uncertain, and why preclinical mechanism should not be equated with clinical benefit.

• Angiotensin II Beyond Vasoconstriction: A Translational Lens

  2026-10-10

  Angiotensin II is more than a vasopressor signal: it is a mechanistic probe linking receptor activation with vascular remodeling and inflammation. This thought-leadership analysis examines the Asp-Arg-Val-Tyr-Ile-His-Pro-Phe peptide through the lens of macrophage polarization, Cx43/NF-κB signaling, study design, reagent provenance, and translational applicability. It also explains how research teams can interpret findings across hypertension mechanism study, vascular smooth muscle cell hypertrophy research, cardiovascular remodeling investigation, and abdominal aortic aneurysm model development without overstating evidence from cell-based systems.

• Proteinase K as a Probe of Candida EV Biology

  2026-10-09

  Proteinase K is more than a DNA-preparation reagent: it can serve as a conceptual probe for distinguishing exposed, membrane-protected, and functionally relevant proteins in Candida albicans extracellular vesicles. This article connects enzyme mechanism with the 2026 NRG1 study while emphasizing evidence strength, study design, and applicability limits.

• Curcumin, Wnt/β-Catenin, and Intestinal Repair

  2026-10-09

  A study in Toxicology and Applied Pharmacology reports that curcumin alleviated DSS-induced colitis while restoring intestinal epithelial organization and intestinal stem cell differentiation, with evidence implicating Wnt/β-catenin signaling and SOX9. The work is mechanistically informative but remains preclinical, so its findings should not be treated as evidence of clinical efficacy in ulcerative colitis.

• Clusterin, Oxidative Stress, and Colitis Barrier Injury

  2026-10-08

  A 2026 study links reduced clusterin (CLU) expression with more severe ulcerative colitis and shows, across human, mouse, and epithelial-cell models, that CLU deficiency worsens oxidative injury, mitochondrial dysfunction, and barrier disruption. The findings position CLU as a regulator of intestinal redox homeostasis through an AKT-associated Keap1–Nrf2 pathway, while leaving open important questions about clinical translation.

• Masitinib (AB1010) Product Overview

  2026-10-08

  Masitinib (AB1010), SKU A2942, is supplier-described as a phenylaminothiazole-type tyrosine kinase inhibitor focused on KIT and PDGFR signaling. No matched paper evidence was provided, so reported potency, disease-model, and clinical claims cannot be independently assessed here.

• HIV-1 Protease Autoprocessing in Drug Discovery

  2026-10-07

  Huang et al. developed and validated a cell-based AlphaLISA platform that targets HIV-1 protease autoprocessing rather than only the mature enzyme. The study showed selective detection of known HIV protease inhibitors and reproduced resistance-associated effects, while also defining important boundaries for interpreting high-throughput protease inhibition data.

• VEGFC–Macrophage Signaling in NASH Fibrosis

  2026-10-07

  A 2026 Phytomedicine study identifies a hepatocyte-derived VEGFC–macrophage regulatory axis that contributes to high-fat-diet-associated liver inflammation and fibrosis. By combining mouse, genetic, cell-based, clinical, and public-transcriptomic evidence, the study positions VEGFC signaling as a mechanistic link between steatotic hepatocytes and inflammatory macrophage behavior, while also defining important limits on translation.

• Angiotensin II and AAA Biomarker Interpretation

  2026-10-06

  Angiotensin II can connect vascular signaling with abdominal aortic aneurysm biology, but biomarker evidence must be interpreted carefully. This article examines the mechanistic link between peptide-driven calcium signaling and the senescence-related ETS1–ITPR3 findings reported in a recent AAA study.

• (S)-Mephenytoin and CYP2C19 Organoids

  2026-10-06

  (S)-Mephenytoin is a CYP2C19 substrate used to examine oxidative drug metabolism. The 2025 organoid study supports hiPSC-derived intestinal epithelial models for pharmacokinetic studies, but it does not by itself validate (S)-Mephenytoin metabolism in those organoids.

• Isoproterenol and Human Pacemaker Assembloids

  2026-10-05

  Isoproterenol sulfate dihydrate is a pharmacological context for studying beta-adrenergic receptor signaling, while recent human SAN–cardiac plexus assembloids provide a model of neuro-cardiac maturation. The available study supports the assembloid platform and identifies a prosaposin–GPR37 signaling program, but it does not establish that isoproterenol was used or that beta-adrenergic stimulation explains the reported maturation phenotype.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-10-05

  A 2026 study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-associated ubiquitination and proteasomal degradation. Cellular, animal, and clinical observations support the MAPK10–KRT16–RNF213 axis as a mechanistic model and candidate biomarker framework, although its therapeutic relevance requires broader validation.

7983 records 2/533 page Previous Next 12345 下5页 Last page